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Abstract
Psoriasis is a chronic inflammatory-proliferative disease. The course of the disease is unpredictible. Psoriasis can
be divided into two types (adolescence and adult). Psoriatic arthritis is observed among about 25% of the patients.
Familiy history is positive in about 30% of the patients. Long-lasting researches confirmed that psoriasis can coex-
ist with other systemic diseases like for example diabetes. The most typical lesion for psoriasis is red or pink papule
covered by silver or yellow scales. The most common locations are knees, elbows, scalp, sacral area and extensor
sufrace of the limbs. Psoriasis and psoriatic arthritis is not life-threathening disease, but it may be a reason of the
problems with normal family and social life. This is why cooperation with the patients in respect to the treatment
(local, systemic and psychological) is so import.
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Introduction
Psoriasis is a chronic and proliferative disorder of the
skin which has a largely unpredictable course. The preva-
lence of the disease has been estimated at between 2%
and 3% of the population. The most susceptible to the
disease are members of the Caucasian race (particularly
in Scandinavia and northern Europe). On the other hand,
the lowest prevalence has been recorded among Native
American Indians, the Inuits, the Japanese and Chinese
populations. Psoriasis can develop at any age and occurs
in both sexes with equal frequency [1, 2]. 
Two basic types of psoriasis have been distinguished,
depending on the age of onset:
• Type I (juvenile), considerably more common, charac-
terized by autosomal dominant inheritance, with onset
usually occurring between 20 and 40 years of age. The
majority of patients with type I psoriasis carry the HLA-
Cw6 antigen. The course of the disease is more severe,
with high resistance to treatment.
• Type II (adult) usually affects the older population,
between 50 and 60 years of age. HLA-Cw6 is uncom-
mon in this group of patients, while the disease tends
to have a milder course [3].
Arthritic psoriasis is, in turn, associated with HLA-
B27 positivity. This form of the disease is estimated to
affect approximately 5-30% of all psoriasis patients. No
precise data are available, though, because final diag-
nosis is often difficult. This stems from the fact that in
ca. 60% of psoriatic arthritis patients skin symptoms
precede joint symptoms, in 20% – skin and joint symp-
toms present concurrently and in 20% – joint symptoms
occur without any skin symptoms (or the skin is very
mildly affected) [4]. 
Psoriasis is known to have a genetic component.
About 30% of psoriasis patients have a family history
of the condition. Several genes have now been identi-
fied that may cause a predisposition towards psoriasis.
The majority of researchers believe that the pattern of
inheritance for psoriasis probably involves multiple
genes, with variable degrees of genetic penetration.
External factors also play a significant role in the devel-
opment of the disease. Psoriasis is linked to infections,
particularly streptococcal diseases (e.g. guttate psoria-
sis is often preceded by purulent tonsillitis) as well as
severe stress, some drugs (e.g. lithium), mechanical
injuries, sunburns [1, 5]. 
Research spanning a number of years has shown that
psoriasis coexists with systemic diseases such as dia-
betes, hypertension, Crohn’s disease or ulcerative colitis.
Recent studies have investigated the association between
psoriasis and the metabolic syndrome which is a cluster
of medical disorders including abdominal obesity (waist
circumference ≥ 80 cm in women and ≥ 94 cm in men, in
the Caucasian population), elevated serum triglycerides
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(TG ≥ 150 mg/dl) or treatment for hypertriglyceridaemia,
reduced concentration of high-density lipoproteins (HDL)
or treatment for dyslipidaemia, elevated arterial pressure
(≥ 130/85 mm Hg) or treatment of previously diagnosed
hypertension, elevated fasting glucose (> 100 mg/dl) or
previously diagnosed type 2 diabetes [6, 7]. 
Clinical picture and diagnostic criteria
Primary skin lesions in psoriasis are reddish pink
papules covered with silver or yellowish scales. Lesions
of this type may coalesce into larger plaques covering
extensive areas of the skin. The most common locations
for psoriatic plaques are the knees, elbows, scalp, sacral
area and extensor surfaces of the limbs. Phenomena that
are characteristic of psoriasis include the candle-grease
sign (when scratched, psoriatic scales fall off revealing
a shiny candle-like surface) and the Auspitz sign (pinpoint
bleeding resulting from the exposure of blood vessels
under thinned epidermis). Another typical sign occurring
in psoriasis is the Koebner phenomenon, i.e. plaque devel-
opment after mechanical injury to the skin [4].
In clinical terms, several types of psoriasis are distin-
guished (according to the guidelines issued by the Polish
Dermatological Society in 2000) [8].
1. Plaque psoriasis (psoriasis vulgaris), the most common
type of the disease. The skin is covered with infiltrated
erythematous plaques of various sizes, covered with
multi-layered scales. A specific clinical form of the con-
dition, guttate psoriasis, presents as numerous, wide-
ly scattered, erythematous exfoliative drop-like lesions,
several millimetres in diameter:
• eruptive and inveterate,
• chronic plaque psoriasis,
• erythrodermic psoriasis.
2. Pustular psoriasis, characterized by small sterile pus-
tules:
• palmoplantar pustulosis (confined to the hands and
feet), 
• disseminated,
• generalized (von Zumbusch type),
3. Arthropathic psoriasis.
4. Nail psoriasis:
• thimble pitting – small, well defined pits on the nail
surface, ca. 1 mm in diameter, making the nail look
like a thimble,
• oil drop phenomenon – yellowish discolorations of
the nail bed resembling drops of oil under the nail
plate,
• onycholysis – separation of the nail plate from the
nail bed at the free edge, often accompanied by sub-
ungual hyperkeratosis [9]. 
In addition, some dermatologists distinguish the
exudative form of psoriasis which is manifested as slight-
ly moist scaly lesions of lesser severity, covering erythe-
matous lesions confined to skin folds and creases [10].
In very rare cases psoriasis can also affect mucous
membranes, usually the oral cavity and, less frequently,
the genital area [11]. 
Arthropathic psoriasis
Psoriasis-related joint problems are observed in rough-
ly 25% of psoriasis patients. In the majority of cases joint
lesions are secondary to skin lesions, which can consid-
erably accelerate the diagnosis. Nevertheless there are
patients who either exhibit no skin symptoms (isolated
psoriatic arthritis) or experience only minimal skin involve-
ment. It is very common for psoriatic arthritis to be accom-
panied only by lesions affecting nail plates. Such cases
call for close cooperation between the rheumatologist
and dermatologist who, based on minor skin or nail
lesions, are able to diagnose psoriasis. Taking a skin lesion
sample can also be useful, as histopathological features
of psoriatic papules are very distinct. 
Psoriatic arthritis (PA) can have several clinical forms:
1. Distal interphalangeal predominant psoriatic arthritis.
2. Symmetrical polyarthritis.
3. Asymmetrical oligoarticular arthritis.
4. Psoriatic spondylitis.
5. Arthritis mutilans – a rare and severely deforming form
of psoriatic arthritis [12, 13].
Clinical assessment of severity of skin psoriasis
PASI (psoriasis area and severity index) score – the
PASI score, developed in 1970, is based on three clinical
signs: erythema (redness), desquamation (scaling) and
induration (thickness) as three parameters estimated for
each body region separately, taking into account their
intensity and percent of area of skin involved. Intensity
(assessed for all the parameters separately) can be
expressed as score 0 (absent), 1 (mild), 2 (moderate), 
3 (severe) and 4 (very severe). The percentage area affect-
ed by psoriasis is assessed as 0 (no lesions), 1 (< 10%), 
2 (10-30%), 3 (30-50%), 4 (50-70%), 5 (70-90%) or 6 (> 90%).
Four body regions are assessed including the head, trunk,
arms and legs. The maximum PASI score is 72. The high-
er the score, the greater the severity of psoriasis. PASI is
often used in clinical trials to compare response to treat-
ment. It is vital for the patient’s PASI score to be always
calculated by the same physician so that the patient’s
condition and changes in the PASI over time are more reli-
ably assessed. 
BSA (body surface area) – percentage area affected
by psoriatic lesions.
PGA (physician global assessment) – assessment of
psoriatic lesions performed by a physician. The PGA
involves a 7-point scale: 7 (clear, i.e. complete regression
of psoriatic lesions), 6 (minimal), 5 (mild psoriasis), 
4 (mild/moderate), 3 (moderate), 2 (severe) and 1 (very
severe psoriasis). 
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DLQI (dermatology life quality index) is a question-
naire which is used to measure the impact of skin lesions
on the quality of life of patients and assess how the
impact changes in the course of treatment.
ACR (American College of Rheumatology) JC66/68
(joint count) – assessment of severity of joint swelling and
tenderness.
DAS28 (disease activity score) – index used to evalu-
ate the extent of joint destruction. 
Psoriasis therapy
Psoriasis vulgaris is not usually a life-threatening dis-
ease, however it may have a significant adverse impact
on the patient’s family and social life. It can also be a con-
tributing factor to emotional disturbances or even depres-
sion. 
Proper daily skin care and moisturization routine play
a vital role in therapy. Typically, moisturizing and oil restor-
ing agents are used, which contain lipid substances and
bind water to a considerable extent. The agents should
be used by psoriasis patients also during periods of remis-
sion [14].
Local therapy
Local therapy typically begins with exfoliating prod-
ucts based on salicylic acid, lactic acid or urea – in order
to remove scales and improve the penetration of subse-
quently applied topical preparations [15].
The next stage is anti-proliferative and anti-inflam-
matory treatment. The most commonly used medications
contain cignolin (dithranol) at concentrations ranging
between 0.03% to 2%. The therapy is very effective and
no major side effects are observed even after prolonged
use. Dithranol inhibits DNA synthesis and cell enzymes,
which in effect reduces epidermal proliferation. The prod-
ucts can be used in minute or hour therapy depending on
the concentration [16]. 
New medications used in local therapy include vita-
min D3 derivatives: calcipotriol, tacalcitol and calcitriol, as
well as retinoids: tazarotene. Vitamin D analogues sup-
press the proliferation of keratinocytes, stimulate proper
keratinization and reduce inflammatory infiltration. Sim-
ilar effects, though resulting from a different mechanism
of action, can be achieved with tazarotene [16-18]. 
Also, pimecrolimus and tacrolimus, two calcineurin
inhibitors, have recently been introduced into psoriasis
treatment. The two substances, which exhibit anti-inflam-
matory action by inhibiting the release of cytokines from
T cells, are particularly recommended for the treatment
of facial lesions [17, 19, 20].
Topical corticosteroids are another important class of
psoriasis drugs. Unfortunately, they tend to be overused.
Despite rapid improvement of the clinical condition, they
produce considerably shorter remissions in monothera-
py. As a result, they are frequently combined with cigno-
lin and vitamin D analogues [16, 17].
Systemic treatment
Patients with severe lesions that are resistant to top-
ical therapy are treated with oral preparations. Vita-
min A derivatives (retinoids) are frequently prescribed.
The medications normalize the process of proliferation
and differentiation of keratinocytes as well as exerting
anti-inflammatory and immunomodulatory effects. This
class of drugs, however, is associated with multiple
adverse reactions, especially teratogenic effects. Anoth-
er effective regimen is based on the combination of sys-
temic retinoids with PUVA (called Re-PUVA) and topical
therapy with cignolin and vitamin D derivatives [21, 22]. 
Cyclosporine, a potent selective immunosuppressant
agent, has also been widely used in psoriasis therapy. The
drug acts by blocking calcineurin phosphatase and thus
preventing lymphocytic activation [21, 23].
Folic acid antagonist methotrexate, the most com-
monly prescribed oral psoriasis drug worldwide, inhibits
cell proliferation, reduces the synthesis of pro-inflam-
matory cytokines and shows immunomodulatory activ-
ity [21, 24]. 
Another drug producing favourable results in the treat-
ment of psoriasis and psoriatic arthritis is sulfasalazine.
The drug is an inhibitor of lipoxygenase pathway of arachi-
donic acid metabolism in human neutrophils, suppress-
ing the generation of leukotrienes [21]. 
One of the most frequently applied therapies is pho-
totherapy. The preferred therapeutic option is UVB nar-
rowband (311 nm) treatment which can be combined with
topical therapy with cignolin or analogues of vitamin D3.
PUVA photochemotherapy is a combination of oral pso-
ralens followed by UVA irradiation (320-400 nm). Bath
PUVA is a variant of phototherapy in which the patient
soaks in a bath containing a aqueous solution of pso-
ralens [25].
Biological drugs are the latest addition to the list of
agents used against psoriasis and psoriatic arthritis. There
are currently three biological drugs available on the Pol-
ish market, which act against proinflammatory cytokine
tumour necrosis factor α (TNF-α): etanercept – a fusion
protein, soluble TNF-α receptor with human Fc; infliximab
– a chimeric anti-tumour necrosis factor α monoclonal
antibody; and adalimumab – an anti-tumour necrosis fac-
tor αmonoclonal antibody with heavy and light chain vari-
able regions and human IgG1 Fc constant regions. The TNF
is a proinflammatory cytokine which plays an important
role in the development of psoriasis. It is involved in elic-
iting an inappropriate immune response which leads to
a chronic inflammation, tissue damage and pathological
activation of keratinocytes. If TNF activity is reduced,
symptoms of the disease subside. A new addition to the
class of biological drugs is ustekinumab, a human mon-
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oclonal antibody directed against interleukin 12 and inter-
leukin 23. The product is approved to treat moderate to
severe and severe psoriasis vulgaris [26, 27]. 
In Poland, criteria for the selection of psoriasis
patients for biological treatment are defined by derma-
tologists and rheumatologists. To qualify for treatment,
the patient’s PASI, BSA, DLQI scores must be higher than
10 and the disease must either be resistant to or there
must be contraindications to at least two types of sys-
temic treatment. 
The treatment of psoriasis and psoriatic arthritis is
based on anti-TNF drugs. The year 2010 saw the publica-
tion of results of PRESTA, a multicentre trial assessing the
efficacy of different doses of etanercept in the treatment
of plaque psoriasis and psoriatic arthritis. The trial
assessed PGA, PASI, BSA, ACR, enthesitis and percentage
of joints in which tenderness and swelling were reduced
(ACR20, ACR50, ACR70) [28]. 
The trial was conducted in a total of 752 patients, of
which 379 were given etanercept 50 mg twice a week for
12 weeks followed by once a week for another 12 weeks,
while 373 received etanercept injections (50 mg) once
a week. At 12 weeks, a substantial improvement of skin
lesions occurred to a greater extent in patients receiving
the drug twice a week. On the other hand, an assessment
of joint complaints revealed no significant differences
between both dose arms. At 24 weeks, the improvement
in joint and skin lesions was comparable in both groups
of patients. PASI 75 at 24 weeks was achieved in 70% of
patients in the higher dose group and 62% in the lower
dose group. The PGA score 7 or 6 at 24 weeks was con-
firmed in 56% and 50% of patients, respectively. A marked
improvement was also noted for enthesitis – in 87% of
patients in both trial arms at 24 weeks. ACR 20, 50 and
70 at 24 weeks was achieved in the higher dose group in
69%, 52% and 35% of patients, respectively; and in the
lower dose group in 72%, 54% and 37% of patients.
Regarding PGA scores, improvement noted at 12 and 24
weeks was comparable: 60% and 62% for patients treat-
ed with higher doses, and 73% and 74% for patients
receiving lower doses. No differences in safety profile were
observed between the two dose groups [28].
Biological drugs are a new class of drugs which act on
specific molecules involved in the pathogenesis of psori-
asis. In the future they may revolutionize the treatment
of moderately severe and severe forms of psoriasis. Obser-
vations conducted to date show them to be both highly
effective and safe, however no data on long-term effects
of the therapy are available yet [29]. Studies are in
progress.
Conclusions
The spectrum of therapeutic options available for top-
ical and systemic treatment of psoriasis is increasing, as
studies are constantly being conducted into new active
substances against the disease. An important aspect
which must not be overlooked, however, is the role of bal-
neotherapy and psychological counselling/therapy in pso-
riasis treatment, which are vital components comple-
menting pharmacological treatment. 
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